jyongbio.com (MENS) - היקף יתרות מזומנים למניה

Can Jyong Biotech Ltd (MENS) successfully scale sales of its plant-based urological treatments? The company leverages Taiwanese research by delegating product manufacturing to contract partners. The stock's outlook depends on success in treating sexual dysfunction and expansion across Asia. The cash per share forecast visualizes liquidity, while 0.02 shows the current value of the metric.
פילוחים אנליטיים של חברת Jyong Biotech Ltd

The stability of Jyong Biotech Ltd (MENS) attracts investors through the analysis of liquid capital, defined as the ratio of total cash to the number of shares to assess the real value of an owner's stake. The trend in calculated cash per share confirms the company's ability to fund a highly specialized staff of biotechnologists and hire compliance experts without resorting to expensive external capital.